These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 24902761)
1. Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity. Paulsen IF; Chakera AH; Schmidt G; Drejøe J; Klyver H; Oturai PS; Hesse B; Drzewiecki K; Mortensen J Clin Physiol Funct Imaging; 2015 Jul; 35(4):301-5. PubMed ID: 24902761 [TBL] [Abstract][Full Text] [Related]
2. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA. Casara D; Rubello D; Pilati P; Scalerta R; Foletto M; Rossi CR Nucl Med Commun; 2004 Jan; 25(1):61-6. PubMed ID: 15061266 [TBL] [Abstract][Full Text] [Related]
3. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma. Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586 [TBL] [Abstract][Full Text] [Related]
4. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187 [TBL] [Abstract][Full Text] [Related]
5. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986 [TBL] [Abstract][Full Text] [Related]
6. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique. Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854 [TBL] [Abstract][Full Text] [Related]
7. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406 [TBL] [Abstract][Full Text] [Related]
9. Isolated limb perfusion for unresectable melanoma of the extremities. Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572 [TBL] [Abstract][Full Text] [Related]
10. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605 [TBL] [Abstract][Full Text] [Related]
11. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Kroon HM; Moncrieff M; Kam PC; Thompson JF Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289 [TBL] [Abstract][Full Text] [Related]
12. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial. Olofsson Bagge R; Mattsson J; Hafström L Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818 [TBL] [Abstract][Full Text] [Related]
13. The use of isolated limb perfusion to manage recurrent malignant melanoma. Ma D; Ariyan S Clin Plast Surg; 2000 Jul; 27(3):441-50, ix. PubMed ID: 10941564 [TBL] [Abstract][Full Text] [Related]
14. Results of hyperthermic perfusion for melanoma of the extremities. Stehlin JS; Giovanella BC; de Ipolyi PD; Muenz LR; Anderson RF Surg Gynecol Obstet; 1975 Mar; 140(3):339-48. PubMed ID: 1114425 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. Olofsson R; Mattsson J; Lindnér P Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. Boesch CE; Meyer T; Waschke L; Merkel S; Goehl J; Hohenberger W; Knorr C Int J Hyperthermia; 2010 Feb; 26(1):16-20. PubMed ID: 20100048 [TBL] [Abstract][Full Text] [Related]
17. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma]. Kettelhack C; Hohenberger P; Schlag PM Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487 [TBL] [Abstract][Full Text] [Related]
18. Circuit and protocol for hypoxic hyperthermic isolated limb perfusion to treat malignant melanoma. Innet LM; Haripershad V; Van Den Berg J; Cooper L Perfusion; 2001 Jul; 16(4):325-30. PubMed ID: 11486853 [TBL] [Abstract][Full Text] [Related]
19. A simplified procedure for continuous intraoperative external monitoring of systemic leakage during isolated limb perfusion. Casara D; Rubello D; Pilati PL; Scalerta R; Foletto M; Rossi CR Tumori; 2002; 88(3):S61-3. PubMed ID: 12369560 [TBL] [Abstract][Full Text] [Related]